Global Hunter Syndrome Treatment Market to Grow at a CAGR of 6.30% During 2024-2032, Aided by the Growing Focus on Treating Rare Diseases

As various governments are enhancing the focus on treating rare diseases, the demand for hunter syndrome treatment is rising. The commercialisation of innovative hunter syndrome treatments and therapies is also propelling the market growth. With the initiation of clinical trials to determine the effectiveness of new treatments for hunter syndrome, the market is poised to witness robust growth. In addition, stem cell-based gene therapy is increasingly investigated to treat children with hunter syndrome, which is likely to fuel the market’s expansion. The increasing research activities to develop new therapies that are designed to deliver proteins to peripheral tissues and the brain for treating somatic symptoms as well as neuronopathic features of hunter syndrome are expected to augment the market growth in the forecast period.

REGENXBIO Inc. (NASDAQ: RGNX), one of the leading companies in the market, announced in February 2022 the additional positive interim data from Cohort 1-3 of the ongoing Phase I/II trial of RGX-121. RGX-121 is an investigational one-time gene therapy that is designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector. It is being investigated for the treatment of patients up to 5 years old that are diagnosed with Hunter Syndrome, also known as Mucopolysaccharidosis Type II (MPS II). The company announced that the interim data demonstrates neurodevelopmental trajectories in patients from Cohorts 1 and 2 and dose-dependent reductions in CSF biomarkers across cohorts. Moreover, the data support the early positive signals that are witnessed in the emerging clinical profile of RGX-121 for hunter syndrome treatment.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Treatment Type, Complication, Route of Administration, End Use, Distribution Channel, and Region:

• The market, on the basis of treatment type, can be divided into enzyme replacement therapy (ERT), and haematopoietic stem cell transplant (HSCT), among others.

• Based on complication, the market can be divided into respiratory disorders, neurological disorders, cardiovascular, musculoskeletal, gastrointestinal disorders, ophthalmic, audiologic, and dental, among others.

• The major routes of administration of hunter syndrome treatment include intravenous and intracerebroventricular (ICV)/ intrathecal.

• By end uses, the market is categorised into hospitals and speciality clinics, among others.

• On the basis of distribution channels, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy, among others.

• The regional markets for hunter syndrome treatment include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The surging healthcare expenditure, the growing awareness regarding rare diseases, and orphan drug development are bolstering the market growth of human syndrome treatment.

• The market is being propelled by the surging investments in research and development (R&D) activities in the novel treatment of hunter syndrome.

• The rising accessibility of innovative treatments and therapies for hunter syndrome treatment is fuelling the market growth.

• The growing prevalence of enzyme replacement therapy (ERT) owing to its fewer side effects and wide availability is augmenting the market’s expansion.

Key Offerings of the Report:

• The EMR report gives an overview of the global market for hunter syndrome treatment for the periods (2018-2023) and (2024-2032).

• The report also offers the historical (2018-2023) and forecast (2024-2032) markets for the treatment types, complications, routes of administration, end uses, distribution channels, and major regions of hunter syndrome treatment.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global hunter syndrome treatment market are Denali Therapeutics Inc., ArmaGen, Inc., Sangamo Therapeutics Inc., CANbridge Life Sciences Ltd. and REGENXBIO Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.